Hap Trading, LLC Cyma Bay Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $884,100 - $1.71 Million	70,000 New	70,000 $163 Million
Q1 2022 May 12, 2022	SELL	$2.77 - $3.64 $50,691 - $66,612	-18,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $59,109 - $84,180	18,300 New	18,300 $6,000
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $53,721 - $83,185	-12,700 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $29,223 - $46,053	-5,100 Reduced 28.65%	12,700 $7,000
Q3 2020 Nov 13, 2020	BUY	$3.32 - $7.24 $21,580 - $47,060	6,500 Added 57.52%	17,800 $46,000
Q2 2020 Aug 10, 2020	BUY	$1.41 - $4.25 $15,933 - $48,025	11,300 New	11,300 $5,000
Q4 2019 Feb 11, 2020	SELL	$1.33 - $5.93 $165,718 - $738,878	-124,600 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $3,584 - $5,047	700 Added 0.56%	124,600 $13,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $749,595 - $1.69 Million	123,900 New	123,900 $130,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.